Eisai remains deeply committed to a patient-centered approach in Alzheimer's care and ensuring LEQEMBI (R) is available to those eligible and living with early AD in Canada. We will continue to pursue ...

Eisai has added another strand to its budding podcast network, bankrolling the “Rethinking Alzheimer's Disease” miniseries to spread information about the prevention and diagnosis of the condition.

If you are wondering whether Eisai is quietly becoming a value opportunity or just a value trap, you are in the right place to unpack what the current share price is really implying. The stock has ...

Eisai (TSE:4523) has been drawing attention after mixed recent returns, including a 1 day decline and a loss over the past month, even though its total return over the past year remains positive. See ...

Eisai officially launched its new U.S. headquarters just as the Japanese pharma looks to expand its commercial presence with an Aduhelm follow-up in Alzheimer’s disease by “building trust with the ...

A month after Eisai reported positive, topline phase 3 data of its Alzheimer’s treatment lecanemab, STAT News is out with a new bombshell report that gut-checks the drug’s hype. The health and science ...

Early launch plans for closely-watched Alzheimer’s drug Leqembi went off without a hitch, say execs from Japanese pharma company Eisai. The product’s long-term viability, though, depends on securing ...

For the estimated 6.7 million older Americans with Alzheimer’s disease—and their loved ones—reasons for hope are rare. Since 2003, 98% of clinical trials for Alzheimer’s treatments have failed. But ...

Regarding its Alzheimer’s drug Leqembi, Eisai released a flash update on February 6 indicating growth is proceeding according to plan. The company highlighted that fiscal year 2027 could see ...

More than 12 hours since Eisai and Biogen announced a phase 3 victory for their Alzheimer’s drug lecanemab, much of the biotech world has become completely giddy. And rightfully so (should the raw ...

Eisai now has the most detailed look yet at the clinical trial data for its Alzheimer’s disease drug lecanemab, with results showing reductions in telltale disease indicators and a slowing of clinical ...

Eisai is expanding the scope of its cancer drug pipeline through a partnership with Bliss Biopharmaceutical, whose lead program addresses a hot oncology target that makes it a potential competitor to ...